Phase 1 Trial Begins Evaluating Safety of Focused Ultrasound in Alzheimer’s Patients

Phase 1 Trial Begins Evaluating Safety of Focused Ultrasound in Alzheimer’s Patients
Insightec’s new platform, Exablate Neuro, is to be a part of the first-ever clinical trial (NCT02986932) evaluating the safety and feasibility of opening the blood-brain barrier (BBB) in Alzheimer’s disease patients at Sunnybrook Health Sciences Centre in Toronto, Canada. Exablate Neuro uses a technique called focused ultrasound, a noninvasive therapeutic technology. It applies ultrasonic energy to

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

9 comments

  1. Joseph Tordone says:

    I will come to you in Canada to have my wife included in this possible therapy. Can you let me know the details on next steps?

Leave a Comment

Your email address will not be published. Required fields are marked *